OTC Recalls Aside, J&J Says Business Still Burdened By Economic Factors
This article was originally published in The Rose Sheet
Executive Summary
Johnson & Johnson concedes that even without the fallout from a recent string of OTC drug recalls, its consumer healthcare business would have been "flat to slightly down" for the quarter
You may also be interested in...
People In Brief
J&J reorganizes QC functions: New company-wide framework will help "facilitate more effective coordination of Johnson & Johnson's quality, compliance and supply chain organizations," according to Corporate Communication VP Jeffrey Leebaw. The spokesman said in an e-mail that CEO William Weldon announced the plan internally the week of Aug. 15 and appointed Corporate VP Ajit Shetty to oversee the new framework. Chief quality officers also will be named for J&J's consumer, pharmaceutical and medical device businesses, Leebaw added. Recalls of OTCs made by J&J's McNeil Consumer Healthcare subsidiary have prompted FDA and congressional investigations and the firm has spent much of 2010 addressing manufacturing shortcomings (1"The Rose Sheet" July 26, 2010)
People In Brief
J&J reorganizes QC functions: New company-wide framework will help "facilitate more effective coordination of Johnson & Johnson's quality, compliance and supply chain organizations," according to Corporate Communication VP Jeffrey Leebaw. The spokesman said in an e-mail that CEO William Weldon announced the plan internally the week of Aug. 15 and appointed Corporate VP Ajit Shetty to oversee the new framework. Chief quality officers also will be named for J&J's consumer, pharmaceutical and medical device businesses, Leebaw added. Recalls of OTCs made by J&J's McNeil Consumer Healthcare subsidiary have prompted FDA and congressional investigations and the firm has spent much of 2010 addressing manufacturing shortcomings (1"The Rose Sheet" July 26, 2010)
J&J Extends Leading Skin-Care Brands With Kits Featuring Cytomimic
Capitalizing on momentum in its skin-care business, Johnson & Johnson is introducing new Cytomimic technology to its Aveeno, Neutrogena and RoC brands with dual-product kits for anti-aging needs around the clock